Licensing

CHO cells engineered to improve production of recombinant proteins

WO 2015/010088
Title: METHODS FOR MODELLING CHINESE HAMSTER OVARY (CHO) CELL METABOLISM
The technology enables computational analysis as well as characterisation of biological networks at the cellular level of Chinese Hamster Ovary (CHO) cells. Based on computer algorithm analysis, utilising a hamster reference genome, the technology is to be used for identifying CHO cell lines having a desired genetic trait. Moreover, the technology may be applicable for generation of CHO cell lines, with the genetic basis of a desired phenotype. Finally, the technology enables construction and analysis of in silico models of biological networks in CHO cells.

WO 2016/091268
Title: N-GLYCOSYLATION
The technology can be used for generation of mammalian cells, including CHO cells, comprising a gene encoding a polypeptide of interest, expressed with one or more posttranslational modifications. The technology is applicable for producing glycoproteins and uses thereof. Thus, the technology may be used for genome engineering, cell culture, protein production and protein glycosylation and use of resulting recombinant protein.

WO 2017/008982
Title: PRODUCTION OF N-GLYCOPROTEINS FOR ENZYME ASSISTED GLYCOMODIFICATION
The technology can be used for generation of mammalian cells, including CHO cells, comprising a gene, encoding a polypeptide of interest with one or more posttranslational modification patterns. More specifically, the technology enables generation of cells with one or more glycosyltransferase genes inactivated, hereby enabling production of N-glycans with monoantennary structure. These modifications are useful for example in improvement of pharmacokinetic properties, i.e. by attaching PEG chains to proteins.

WO 2017/186671
Title: ENGINEERED MAMMALIAN CELLS FOR PRODUCTION OF RECOMBINANT PROTEINS
The technology can be used to generate mammalian cells, genetically modified to provide for improved expression of a recombinant protein. The technology is based on generation of host (CHO) cells, in which the expression of one or more endogenous secreted proteins is disrupted. The technology relates to the preparation, identification and use of such cells when producing recombinant proteins.

WO 2018/033542
Title: METHOD FOR REDUCING AMMONIUM AND LACTATE PRODUCTION IN CHO CELLS
The technology enables modification of mammalian producer (including CHO) cell lines to obtain improved production of therapeutic proteins. Specifically, removing genes involved in amino acid catabolism in CHO cells, improves cell growth and viability, enabling higher yield of a recombinant therapeutic protein produced by the modified cells.

WO 2017/192437
Title: MAMMALIAN CELLS DEVOID OF LACTATE DEHYDROGENASE ACTIVITY
The technology is a mammalian cell line (including CHO) genetically engineered to be completely devoid of lactate dehydrogenase activity and therefore, to produce zero lactate. As a result, the technology enables the cells to be cultured at higher maximum cell density, while growing at a normal rate, e.g., compared to the wildtype mammalian cell.